Results 41 to 50 of about 87,697 (243)

Multiple urinary bladder masses from metastatic prostate adenocarcinoma

open access: yesRare Tumors, 2010
We present an unusual case of metastatic prostate adenocarcinoma that manifested with multiple exophytic intravesical masses, mimicking a multifocal primary bladder tumor.
Richard Choo   +4 more
doaj   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

open access: yesMolecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley   +5 more
wiley   +1 more source

Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms. [PDF]

open access: yes, 2014
Losses in the succinate dehydrogenase (SDH) complex characterize 20% to 30% of extra-adrenal paragangliomas and 7% to 8% of gastric GISTs, and rare renal cell carcinomas.
Biernat, Wojciech   +9 more
core   +1 more source

Presacral Schwannoma Resembling Lymph Node Metastasis in a Patient with Locally Advanced Prostate Cancer

open access: yesIndonesian Journal of Cancer
Introduction: SSchwannomas originating in the pelvic region are rare and present diagnostic challenges when they coexist with malignancies. Case Presentation: A 58-year-old man with urinary frequency and an elevated prostate-specific antigen ...
Yukihiro Hama, Etsuko Tate
doaj   +1 more source

Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early‐stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mice (Lox‐STOP‐Lox‐KrasG12D/+ Lox‐STOP‐Lox‐Trp53R172H/+ Pdx1‐Cre) before PDAC development and also early‐stage PDAC patients (n = 31), compared to benign ...
Hannah Mearns   +10 more
wiley   +1 more source

Report of Frequency of Prostatic Adenocarcinoma Stage A in Patients Operated due to BPH

open access: yesپزشکی بالینی ابن سینا, 2003
In this study 1192 cases were studied from 1986 to1996 in Imam Khomeini and Ekbatan hospitals of Hamadan province.           75 cases were found having pathologic stage A cancer (occult cancer).
Hooshang
doaj  

Metabolic syndrome and prostatic disease: potentially role of polyphenols in preventive strategies. A review

open access: yesInternational Brazilian Journal of Urology, 2016
Benign prostatic hyperplasia and prostate cancer are two common urological diseases of the elderly. Scientific community has always looked for a link that could explain the correlation between the two diseases and the role of chronic inflammation in the ...
Tommaso Castelli   +8 more
doaj   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

open access: yesMolecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos   +6 more
wiley   +1 more source

A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma [PDF]

open access: yes, 2017
Aims: CDX2 is widely used as a sensitive and specific immunomarker for colorectal carcinoma (CRC) but neither this sensitivity nor specificity is absolute. This study is the first known comparison of CDX1 and A33 against CDX2 as immunomarkers for CRC.
Adamczyk, Lukasz A.   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy